Evidence map›Paper›PMID 40321450›Full record

ArticleGlobal health & medicine2025

Large-scale screening of SARS-CoV-2 variants in Tokyo, Japan: A 3-year and 9-month longitudinal survey.

Junko S Takeuchi, Kei Yamamoto, Masami Kurokawa, Kento Fukano, Azusa Kamikawa, Emiko Hatano, Sakino Takayanagi-Nishisako, Ayano Motohashi, Yuki Takamatsu, Hiroaki Mitsuya and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global health & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Junko S TakeuchiBiorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Kei YamamotoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Masami KurokawaDepartment of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Kento FukanoBiorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Azusa KamikawaBiorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Emiko HatanoBiorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Sakino Takayanagi-NishisakoBiorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Ayano MotohashiDepartment of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Yuki TakamatsuDepartment of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Hiroaki MitsuyaDepartment of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Moto KimuraBiorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Wataru SugiuraCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over nearly four years (March 10, 2021-December 31, 2024), we performed a comprehensive longitudinal analysis of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants among patients in a single hospital in Tokyo, Japan. Using RT-qPCR and Sanger sequencing, complemented by whole-genome sequencing, we tested nasopharyngeal swab samples (

Indexed as

clinical dataCOVID-19epidemiologysequencingvariant of concern (VOC)

Identifiers

PMID40321450
PMCPMC12047035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.